Fig 1.
Characterization of ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen in ICU patient samples.
(A) ADAMTS13 activity in septic patients, non-septic patients, and healthy controls (day 1). (B) ADAMTS13 activity in non-survivors septic (NS), survivor septic (S), non-septic, and healthy controls at day 1 and day last. (C) ADAMTS13 antigen in septic patients, non-septic patients, and healthy controls (day 1). (D) ADAMTS13 antigen in non-survivors septic, survivor septic, non-septic, and healthy controls at day 1 and day last. (E) VWF antigen levels in septic patients, non-septic patients, and healthy controls (day 1). (F) VWF antigen in non-survivor septic, survivor septic, non-septic, and healthy controls at day 1 and day last. All ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen values normalized to pooled healthy control plasma and expressed as percentage (mean±SD). Dunnett’s multiple comparisons test (one-way ANOVA). Paired t-test performed to assess change between day 1 and day last. ****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05, and N.S. p>0.05.
Table 1.
Various patient characteristics recorded upon admission to ICU. Healthy controls were not admitted.
Fig 2.
Comparison of ratio of ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen in ICU patient samples.
(A) Day 1 ADAMTS13 activity to antigen ratio in non-survivor septic (NS), survivor septic (S), non-septic, and healthy controls. (B) Day last ADAMTS13 activity to antigen ratio in non-survivor septic, survivor septic, and non-septic ICU. (C) Day 1 ratio of VWF AG:ADAMTS13[AC:AG] in non-survivor septic, survivor septic, non-septic, and healthy controls (D) Day last ratio of VWF AG:ADAMTS13 [AC:AG] in non-survivor septic, survivor septic, non-septic, and healthy controls. ADAMTS13 activity, ADAMTS13 antigen, and VWF antigen values normalized to pooled healthy control plasma and expressed as a percentage (mean±SD). Dunnett’s multiple comparisons test (one-way ANOVA). ****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05, and N.S. p>0.05.
Fig 3.
Comparison of Myeloperoxidase and Protein C in ICU patient samples.
(A) MPO levels in non-survivor septic (NS), survivor septic (S), non-septic, and healthy controls at day 1 and day last. (B) Protein C levels in non-survivor septic, survivor septic, non-septic, and healthy controls at day 1 and day last. MPO and Protein C values normalized to pooled healthy control plasma and expressed as a percentage (mean±SD). Dunnett’s multiple comparisons test (one-way ANOVA). Paired t-test performed to assess change between Day 1 and Day Last. ****p≤0.0001, ***p≤0.001, **p≤0.01, *p≤0.05, and N.S. p>0.05.